Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Part D Discount Early Recipients Get $38 Mil. Off Brand Prices In First Two Months Of 2011

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

More than 47,000 enrollees reached the Medicare coverage gap and received 50% discounts on brand drugs through Feb. 28, HHS announced March 22.

You may also be interested in...



OIG's 2012 Agenda Includes Several New Part D, Part B Drug Issues

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Final ICH Guide Supports Nonclinical Development Of Gene Therapy Products

NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others

Canadian Action On Rare Disease Is A ‘Step Forward,’ Says Industry

Three Firms Sign Up With MPP For Long-Acting Cabotegravir

See All
UsernamePublicRestriction

Register

PS071995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By